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BACKGROUND OF THE INVENTION
Trauma, pathological degeneration, or congenital defor mity of tissues often requires Surgical reconstruction or replacement. The defective tissues need to be replaced with viable, functioning alternatives. In skeletal applications, Sur geons have historically used bone grafts, primarily autografts and allografts. However, both types of grafts have significant disadvantages. For example, there is the problem of donor site morbidity where damage occurs at the harvest site caused by removal of the graft. In addition, there is only a limited amount of bone available for harvesting. Furthermore, autografts have unpredictable resorption characteristics. With allografts there are the well-recognized problems associated with adverse immunologic responses to the foreign grafted tissue. As a result, newly grafted tissue is often rejected by the body and induces a severe inflammatory response. Allografts are also capable of transmitting diseases, despite pre-screen ing processes, since pre-screening is not 100% effective.
Conventional orthopedic implants such as screws, plates, pins and rods serve as load-bearing replacements for dam aged bone and are usually composed of a metal or alloy. Although these implants are capable of providing rigid fixa tion and stabilization of the bone, they cause improper bone remodeling of the implant site due to the large difference in the modulus between bone and metal.
Alternative synthetic bone graft substitutes have been the subject of extensive research. Such bone graft substitutes need to be biocompatible, capable of Supporting new bone growth, possess mechanical strength and preferably be bio degradable. However, despite the extensive research in this field, the synthetic bone graft substitutes often fail to meet all of these criteria. Thus, there is a need to provide a biocom patible composite materials that can be fabricated into a scaf fold having properties suitable for bone repair and regenera tion, and methods for making Such materials.
SUMMARY OF THE INVENTION
The present invention provides biocompatible composite materials that can be fabricated into a scaffold having prop erties suitable for bone repair and regeneration. Unlike pre viously described materials, these scaffolds are biocompat ible, biodegradable, and have sufficient mechanical strength to be useful for the repair and regeneration of cortical bones.
One aspect of the invention is a biocompatible composite material comprising functionalized carbon nanotubes and a biodegradable polymer. In one embodiment, the biocompat ible composite material comprising functionalized carbon nanotubes and a biodegradable polymer does not comprise calcium phosphate. The biocompatible composite material comprises a low concentration of carbon nanotubes. The car bon nanotubes are functionalized such that the carbon nano tubes are water dispersible. For example, the carbon nano tubes can be functionalized with carboxyl groups, amide groups, hydroxyl groups, polyethylene glycol (PEG), or any tubes are randomly dispersed in the composite material. In another embodiment, the carbon nanotubes are single wall carbon nanotubes. In another embodiment, the carbon nano tubes are multi-wall carbon nanotubes. In a further embodi ment, the biodegradable polymer comprises, consists essen tially of, or consists of poly(lactic acid-glycolic acid) (PLGA). The biodegradable polymer preferably has a micro sphere shape.
Another aspect of the invention is a biocompatible com posite scaffold material fabricated with the biocompatible composite material described herein. The scaffold material has a compressive modulus value and a compressive strength Suitable for, and compatible with, repair and regeneration of load-bearing bone, such as cortical bone. In one embodiment, the biocompatible composite scaffold material has a com pressive modulus value of at least about 200 MPa to at least about 500 MPa. Furthermore, the biocompatible composite scaffold material has a compressive strength of at least about 5.0 MPa to at least about 50 MPa. Preferably, the scaffold material is sufficiently porous to allow, for example, seeding and growth of cells. In one embodiment, the scaffold material has a porosity of at least about 25%-about 35%, preferably at least about 30% porosity.
In another aspect of the invention, the biocompatible com posite material and/or biocompatible composite scaffold material further comprises one of more further agents. In one embodiment, the agent is a bioactive agent. For example, a bioactive agent is a bone morphogenic protein (BMP), a vascular endothelial growth factor (VEGF), a connective tis Sue growth factor (CTGF), osteoprotegerin, a growth differ entiation factor (GDF), a cartilage-derived morphogenic pro tein (CDMP), a LIM mineralization protein (LMP), a transforming growth factor beta (TGFB), an antibiotic, an immunosuppressive agent, or any combinations thereof.
A further aspect of the invention is a method of producing a biocompatible composite scaffold material. The method comprises dispersing functionalized carbon nanotubes with a biocompatible polymer in a solvent to produce a composite, such as the biocompatible composite material described herein. In one embodiment, ultrasonication is used to disperse the functionalized carbon nanotubes with a biocompatible polymer in a solvent. The composite is thermally sintered using a mold (e.g., a metallic mold) to produce the biocom patible composite scaffold material. In one embodiment, the biocompatible polymer are polymer microparticles. For example, the polymer microparticles can be microspheres. In another embodiment the biocompatible composite scaffold material has a compressive modulus value of at least about 250 MPa and a compressive strength of at least about 7.5 MPa. Another embodiment is a biocompatible composite scaffold material produced by the methods described herein.
A further aspect of the invention is a method of effecting bone repair or bone regeneration in a Subject. The method comprises contacting the bone defect or area needing bone regeneration with a biocompatible composite scaffold mate rial as described herein. In one embodiment, the bone in need of repair or regeneration is cortical bone.
BRIEF DESCRIPTION OF THE DRAWINGS
The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee.
FIG. 1 demonstrates water dispersibility of functionalized carbon nanotubes (FNCTs). The carbon nanotubes were 3 either non-functionalized (pristine) or functionalized with amine ( NH), thiol ( SH), amide ( CONH), polyeth ylene glycol (PEG), carboxyl ( COOH) or hydroxyl (-OH) groups. The pristine, amine, and thiol FCNTs exhibit sedimentation (demonstrating poor water dispersibility), while FCNTs with amide, PEG, carboxyl and hydroxyl groups resulted in uniform dispersion (demonstrating good water dispersibility).
FIG. 2 is a series of photographs demonstrating the biomi metic nature of different water-dispersible FCNT-PLGA composites in simulated body fluid (SBF). Water-dispersible nanotubes (1% wt/wt) were mixed with PLGA 85/15 in acetone and Sonicated for 2 hours. Composite films were cast and vacuum dried. Composite films were immersed in SBF for 7, 14 and 21 days. Mineral deposition was viewed using scanning electron microscopy (SEM). Shown are photo graphs at day 7. Composites showed increased levels of bio mimetic mineral deposition, by day 7, as compared to the control PLGA. In order to provide a clear and consistent understanding of the terms used in the present specification, a number of defi nitions are provided below. Moreover, unless defined other wise, all technical and Scientific terms as used herein have the same meaning as commonly understood to one of ordinary skill in the art to which this specification pertains.
The use of the word "a" or "an' when used in conjunction with the term "comprising in the claims and/or the specifi cation may mean 'one', but it is also consistent with the meaning of "one or more", "at least one', and "one or more than one'. Similarly, the word "another may mean at least a second or more.
As used in this specification and claim(s), the words "com prising (and any form of comprising. Such as "comprise' and "comprises"), "having (and any form of having, such as "have" and "has'), "including (and any form of including, such as "include" and "includes') or "containing (and any form of containing, such as "contain' and "contains'), are inclusive or open-ended and do not exclude additional, unre cited elements or process steps.
The term "about is used to indicate that a value includes minor deviations. Such deviation can be the result of inherent variation from error for the device or the method being employed to determine the value.
As used herein, the following acronyms have the following definitions: CNT: carbon nanotube; SWNT or SWCNT:
single-wall carbon nanotube; MWNT or MWCNT: multi wall carbon nanotube; FCNT: functionalized carbon nano tube; PLGA: Poly(lactic acid-glycolic acid) (also sometimes referred to as PLAGA); PLA: poly lactic acid; PGA: poly glycolic acid; MPa: mega Pascal; SEM. Scanning Electron Microscopy. Bone loss occurs mainly due to trauma, congenital defects, malignant diseases and primary and revision joint Surgeries. The repair and replacement of damaged bone is a major clinical problem in the U.S. and worldwide. In the U.S. alone over a million bone fractures or defects are treated each year, this number is expected to grow as the life expectancy increases and the overall U.S. population is continues to rise. Current bone replacement procedures often use autograft or allograft tissue, but these approaches have limitations. Autografts are often limited in supply and the harvest of these tissues is associated with donor site morbidity. Allografts carry the potential of disease transmission and immunologi cal rejection. Therefore, there exists a need to develop bone graft Substitute materials that could mimic the properties of bone while eliminating the shortcomings of traditional bone grafts such as autografts and allografts.
Synthetic bone graft Substitutes (based on metals, poly mers and ceramics) have been Suggested as alternatives due to their unlimited Supply, easy sterilization and storage. Cur rently available synthetic bone substitutes involve biodegrad able polymers, and their composites with various forms of calcium phosphate with or without bioactive agents. These substitutes have attracted a lot of attention over metallic grafts, because of their transient nature and degradation into body friendly by-products. Composites of biodegradable polymers with hydroxyapatite improved mechanical strength while also improving osteocompatibility of the graft material. However, the existing bone graft materials still suffer from 5 their weak mechanical properties compared to the bone tis Sue. Therefore, there is a strong need to develop biodegrad able polymer composites with bone tissue comparable mechanical properties for bone grafting applications.
Bone tissue engineering is the application of biological, chemical, and engineering principles towards the repair, res toration or regeneration of tissues using cells, factors, and scaffolds alone or in combination. Scaffold based tissue engi neering has become a promising strategy in bone tissue regen eration, because cells alone lack the ability to form three dimensional tissues without the Support of an artificial struc ture referred to as a scaffold. An ideal scaffold should exhibit biocompatibility, biodegradability, mechanical compatibil ity, interconnected porosity and non-toxic degradation prod uctS.
Early efforts using polymeric biodegradable scaffolds demonstrate only weak loadbearing ability which limits their clinical applicability for bone regeneration and repair appli cation. Such scaffolds may be useful for other applications, Such as nerve cell growth and the like. In contrast, the present invention provides biocompatible composite materials that can be fabricated into a scaffold having properties suitable for bone repair and regeneration. These scaffolds have sufficient mechanical strength to be useful for the repair and regenera tion of cortical bone. Cortical bone, also referred to as com pact bone, is one of the two types of osseous tissue that form bones (the other being cancellous bone). Cortical bone facili tates the main functions of bones, namely, Support the body, protect organs, provide levers for movement, and store and release chemical elements, mainly calcium and phosphorous.
Cortical bone forms the cortex, or outer shell, of most bones and is much denser than cancellous bone. Furthermore, cor tical bone is harder, stronger and stiffer than cancellous bone.
Polymer-based materials have been utilized for the con struction of medical devices for many years. Polymers are a class of synthetic materials characterized by their high ver satility. The versatility has led to the development of biode gradable, biocompatible polymers created primarily for use in medical applications. One of the most common polymers used as a biomaterial has been the copolymer poly(lactic acid-glycolic acid) referred to herein as PLGA. PLGA is highly biocompatible, degrades into harmless monomer units and has a wide range of mechanical properties making this copolymer and its homopolymer derivatives, PLA and PGA, useful in medical applications.
Porous, three-dimensional matrices comprising these polymers for use in bone replacement have been prepared using various techniques. Coombes and Heckman (Biomate rials 1992 3:217-224) describe a process for preparing a microporous polymer matrix containing 50:50 PLGA:PLA and 25:75 PLA:PLGA. The polymer is dissolved in poor solvent with heat and the gel is formed in a mold as the polymer cools. Removal of the solvent from the matrix cre ates a microporous structure. However, the actual pore size of this matrix (<2 um) is inadequate for bone ingrowth which requires apore size falling within the range of 100-250 um for cell growth to occur. Furthermore, polymers, such as PLGA, generally lack Sufficient mechanical strength for use in bone repair and regeneration, particularly for cortical bone.
Carbon-based materials have also been the subject of extensive research for biological applications. Structures made of carbon materials have been investigated as Substrates for cell scaffolding and growth. For example, carbon nano tube ("CNT) technology is being applied to medical appli cations, with recent investigations focusing on carbon nano tubes as substrates for the growth of retinal cells, neural cells and endothelial cells. Also, CNT-based composites have been investigated for cartilage regeneration and in vitro cell pro liferation of chondrocytes. Carbon nanotubes are strong and are also capable of being shaped into 3D architectures and are promising in the construction of engineered products for bio logical applications. Carbon is an inert material and thus is generally biocompatible, however, recent studies have raised the concern that carbon nanotubes, so-called "pristine' CNTs have adverse health effects in the body.
Specific Embodiments
Described herein is a biocompatible composite material comprising water dispersible carbon nanotubes and a biode gradable polymer. Water-dispersible carbon nanotubes are carbon nanotubes that form a uniform dispersion or homoge neous Suspension when mixed with water. In contrast, non water-dispersible carbon nanotubes sediment or settle after mixing in water. Also described is a scaffold material suitable for use in bonegrowth and regeneration, as well as methods of making these compositions.
Thus, one aspect of the invention is a biocompatible com posite material comprising water dispersible carbon nano tubes and a biodegradable polymer. In one embodiment, the biocompatible composite material comprising water dispers ible carbon nanotubes and a biodegradable polymer does not comprise calcium phosphate.
Biodegradable polymers, both natural and synthetic, are well known in the art and include, but are not limited to, polylactides, polyglycolides, polycaprolactones, polyanhy drides, polyamides, polyurethanes, polyesteramides, poly orthoesters, polydioxanones, polyacetals, polyketals, poly carbonates, polyorthocarbonates, polyphosphazenes, polyhydroxybutyrates, polyhydroxyvalerates, polyalkylene oxalates, polyalkylene Succinates, poly(malic acid), poly (amino acids), polyvinylpyrrolidone, polyethylene glycol, polyhydroxycellulose, chitin, chitosan, poly(L-lactic acid), poly(lactide-co-glycolide), poly(hydroxybutyrate-co-Valer ate), and copolymers, terpolymers, or combinations or mix tures of the above materials. Suitable biodegradable polymers can be chosen by the person skilled in the art using standard techniques and based on the mechanical and degradation properties of the polymer such that the polymer is chosen for its compatibility with bone regeneration. Biodegradable polymers can be of any suitable form or shape. For example, the biodegradable polymer is a micro particle. In one embodiment, the biodegradable polymer is a microsphere. Such shapes of the biodegradable polymer is advantageous to the forming of pores or channels in a bio compatible composite scaffold material as described herein.
In one embodiment, the biodegradable polymer comprises, consists essentially of, or consists of poly(lactic acid-glycolic acid) (also referred to as poly(lactic-co-glycolic acid) or poly (lactide-co-glycolide)) (PLGA). In one embodiment, the PLGA is 85:15 PLGA (referring to the molar ratio of lactic acid to glycolic acid). In another embodiment, the PLGA is 50:50 PLGA, 65:35 PLGA, and the like.
The biocompatible composite material further comprises a low concentration of water-dispersible carbon nanotubes. In one embodiment, the carbon nanotubes are multi-wall carbon nanotubes. In another embodiment, the carbon nanotubes are single-wall carbon nanotubes. In an alternative embodiment, the carbon nanotubes are a mixture of single-wall and multi wall carbon nanotubes. The concentration of carbon nano tubes is such that carbon nanotubes are not the majority component (e.g., less than about 50% (wit/wt), more prefer ably less than about 10% (wit/wt), still more preferably less than about 5% (wit/wt) of the composite material. In one 7 embodiment, the biocompatible composite material com prises about 7%, 6%. 5%, 4%, 3%, 2%, 1%, 0.5% or less (wt/wt) carbon nanotubes. In a particular embodiment, the biocompatible composite material comprises about 1-4%, about 1-3%, about 2-3%, or about 2-4% (wit/wt) carbon nano tubes. As will be appreciated, the amount of carbon nanotubes optimally achieves the mechanical properties that are com patible for bone repair and regeneration, but which minimizes any potential side effects of the presence of carbon nanotubes in the body.
The carbon nanotubes can vary in size. In one embodiment, the carbon nanotubes are typically about 1-30 nm in diameter and typically about 0.5-30 um in length. In one embodiment, In one embodiment, the carbon nanotubes are randomly dispersed in the composite material. As described herein, in one embodiment, the carbon nanotubes are randomly dis persed on the Surface of polymer microspheres.
Another aspect of the invention is a biocompatible com posite scaffold material fabricated with the biocompatible composite material described herein. In one embodiment, the biocompatible composite scaffold material has a compressive modulus value of at least about 200 MPa to at least about 500
MPa. In another embodiment, the biocompatible composite scaffold material has a compressive modulus value of at least about 250 MPa, about 275 MPa, about 300 MPa, about 325 MPa, about 350 MPa, about 375 MPa, about 400 MPa, about 425 MPa, about 450 MPa, about 475 MPa, or about 500 MPa.
In a further embodiment, the biocompatible composite scaf fold material has a compressive modulus value of about 260+46 MPa. In a another embodiment, the biocompatible composite scaffold material has a compressive modulus value of about 371+27 MPa. Furthermore, the biocompatible com posite scaffold material has a compressive strength of at least has a compressive strength about 7.2:1.51 MPa. In another embodiment, the biocompatible composite scaffold material has a compressive strength about 25.7+1.8 MPa. The scaffold material is sufficiently porous to allow, for example, seeding and growth of cells. In one embodiment, the scaffold material has a porosity of at least about 25%-about 35%, preferably at least about 30% porosity.
In another aspect of the invention, the biocompatible com posite material and/or biocompatible composite scaffold material further comprises one of more agents. Such agents can be, e.g., a bioactive agent, or an inert agent. Inert agents can be any suitable agent, e.g., carrier, excipient, sterilizing Solution, labeling Solution, and the like. Bioactive agents are also known in the art. Examples of antibiotics useful with the biocompatible composite material include, but are not limited to, amoxicil lin, beta-lactamases, aminoglycosides, beta-lactam (glyco peptide), clindamycin, chloramphenicol, cephalosporins, ciprofloxacin, erythromycin, fluoroquinolones, macrollides, metronidazole, penicillins, quinolones, rapamycin, rifampin, streptomycin, Sulfonamide, tetracyclines, trimethoprim, tri methoprim-Sulfamethoxazole, and Vancomycin. Suitable immunosuppressive agents that can be included in the biocompatible composite material, include but are not limited to, steroids, cyclosporine, cyclosporine analogs, cyclophosphamide, methylprednisone, prednisone, azathio prine, FK-506, 15-deoxyspergualin, and other immunosup pressive agents that act by Suppressing the function of responding T cells. Other immunosuppressive agents include, but are not limited to, prednisolone, methotrexate, thalido mide, methoXSalen, rapamycin, leflunomide, mizoribine (BredininTM), brequinar, deoxyspergualin, and azaspirane (SKF 105685), Orthoclone OKTTM3 (muromonab-CD3) SandimmuneTM, NeoraTM, SangdyaTM (cyclosporine), Pro grafTM (FK506, tacrolimus), Cellcept TM (mycophenolate motefil, of which the active metabolite is mycophenolic acid), ImuranTM (azathioprine), glucocorticosteroids, adrenocorti cal steroids such as DeltasoneTM (prednisone) and Hydeltra solTM (prednisolone), FolexTM and MexateTM (methotrexate), Oxsoralen-UltraTM (methoxsalen) and RapamuenTM (siroli mus).
As will be appreciated by those in the art, bioactive agents can be polypeptides, including full length polypeptides, bio logically active fragments thereof, and fusion proteins, Small molecules, and cells expressing Such bioactive agents. Fur thermore, the concentrations of the bioactive agent can be variable based on the desired length or degree of activity required.
A further aspect of the invention is a method of producing a biocompatible composite scaffold material. The method comprises dispersing functionalized carbon nanotubes with a biocompatible microsphere polymer in a solvent to produce composite microspheres, such as the biocompatible compos ite material described herein. In one embodiment, ultrasoni cation is used to disperse the functionalized carbon nanotubes with a biocompatible microsphere polymer in a solvent. Non limiting examples of a suitable solvent include acetone, dichloromethane, and mixtures thereof. The composite microspheres are cast in a suitable mold and then sintered to produce the biocompatible composite scaffold material. In one embodiment, the composite microspheres are sintered at about 95°C., about 100° C., or about 105°C. for about 1 hour.
In another embodiment, the biocompatible composite scaf fold material has a compressive modulus value of at least about 250 MPa and a compressive strength of at least about 7.5 MPa. A further aspect of the invention is a method of effecting bone repair or bone regeneration in a Subject. The method comprises contacting the bone defect or area needing bone regeneration with a biocompatible composite scaffold mate rial as described herein. In one embodiment, the bone in need of repair or regeneration is cortical bone. Thus, in one embodiment is a method of performing a bone repair Surgery on a patient whereby the area of the bone in need of repair or regeneration is accessed and cleaned, preferably using mini mally invasive techniques. The biocompatible composite scaffold material is inserted and positioned in the appropriate area of the bone, and the incision is Surgically closed.
EXEMPLIFICATION Example 1
Water Dispersible Carbon Nanotubes (WDCNTs) Carbon nanotubes (CNTs) were purchased from Cheap Tubes, Inc. (Vermont, USA). Various single and multi-wall functionalized carbon nanotubes were screened for their water dispersibility. 0.1% (wt/vol) of carbon nanotubes (func tionalized or non-functionalized (so called "pristine')) were mixed with water and subjected to sonication for 1 h at room temperature. The Suspension was allowed to stand for 24 h to observe any nanotube settlement. As shown in FIG. 1 , carbon nanotubes functionalized with -CONH2, polyethylene gly col (PEG), -COOH and-OH groups exhibited good water dispersibility. In contrast, non-functionalized (pristine) car bon nanotubes and carbon nanotubes functionalized with -NH and -SH resulted in sedimentation.
Example 2 PLGA-Water Dispersible Carbon Nanotube Composite 2D-Matrices
Composite matrices with water dispersible carbon nano tubes (WDCNTs) (nanotubes with amide, polyethylene gly col, carboxyl and hydroxyl as functional groups) were fabri cated. Two dimensional matrices were studied for biocompatibility and osteocompatibility. The preparation of biodegradable polymers in two dimensional films have been described elsewhere (Deng, et al., 2008 (Deng, et al., , 2009 . Here, water 10 dispersible carbon nanotube composites with poly(85-lac tide-co-15-glycolide) (PLGA) was fabricated into two-di mensional films. Various WDCNTs (1 wt %) were mixed with PLGA in acetone and sonicated for 2 h. Acetone was selected as a solvent because it could solubilize PLGA while also interacting with hydrophilic nanotubes through dipolar inter actions. Uniformly mixed solutions were cast and allowed a slow evaporation at 4°C. The solutions were subjected to constant agitation to prevent nanotube agglomeration. Dried films were bored into 10 mm diameter disks and used for biomineralization and in vitro osteoblast cell proliferation and differentiation studies.
Biomineralization:
Hydroxyapatite layer formation on a biomaterial Surface in simulated body fluid (SBF) is considered an early indication of a material's biocompatibility. In this example, all the com posites were tested in SBF for their biocompatibility. Two dimensional matrices were immersed in SBF for 7, 14 and 21 days and the mineral deposition was analyzed using scanning electron microscopy (SEM). Carbon nanotube composites showed increased levels of biomimetic mineral deposition, by day 7, when compared to the control PLGA (FIG. 2) . Increased bio-mineralization Suggested carbon nanotube functional group interaction with the Surrounding calcium and phosphate ions in SBF. Such interactions could have resulted in mineral phase nucleation and growth. Elemental analysis Suggested the mineral phase as the desired calcium deficient hydroxyapatite. This study confirmed the enhanced biomineralization ability of the novel PLGA-water dispers ible carbon nanotube composite biomaterials.
Cell Proliferation and Osteocompatibility Evaluations (FIGS. 4 and 5):
Nanotube composites were further characterized for their cell compatibility. This study was designed to understand the bone cell interaction with functionalized carbon nanotubes. Mouse MC3T3-E 1 osteoblasts were seeded onto two-dimen sional composite matrices at a density of 5x10" cells per each rounded scaffold of 10 mm diameter. At days 4, 10 and 20, cellularized constructs were taken out of the culture and char acterized for MC3T3-E1 adhesion and spreading (scanning electron imaging), proliferation (PicoGreen dsDNA assay), and calcium deposition (both Alizarin red staining and quan tification). Cell adhesion and growth were quite similar to the observations made on PLGA polymer matrix. Composite matrices with amidefunctional nanotubes showed higher cell proliferation throughout the study. It was also clear that com posite scaffolds exhibited higher levels of calcium deposition at the initial stage and the response was leveled by day 20. Observations were comparable to osteoblast performance with PLGA in terms of proliferation, and mineralization indi cates the non-toxic nature of these functionalized carbon nanotube composites in vitro and their suitability for bone tissue engineering.
Example 3
Carbon Nanotube-PLGA Composite Microspheres and 3D-Scaffolds PLGA-CNT composite microspheres were prepared and fabricated into three dimensional scaffolds which can then be used in bone regeneration. In this example, multi-wall carbon nanotubes functionalized with carboxylic groups were used (referred to herein as MWCNTs). These are 20-30 nm in diameter and 10-30 um in length with 4-5% of carbons func tionalized with -COOH groups. MWCNTs were considered
